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CANDIDURIA IN A PUBLIC HOSPITAL OF SÃO PAULO (1999-2004):
CHARACTERISTICS OF THE YEAST ISOLATES
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SUMMARY
The study involved 100 yeast isolates, obtained from urine samples provided by a Public Pediatric Hospital of São Paulo,
Brazil, from 1999 to 2004. The most frequent species was Candida albicans, followed by C. tropicalis, C. glabrata and C.
parapsilosis. In regard to virulence, 97% of the isolates showed index 3 for proteinase and 63% index 2 for phospholipase. The
most frequent killer biotypes were 511 and 888.
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INTRODUCTION
In the last 20 years, there has been a significant rise in the
occurrence of nosocomial infections due to Candida genus yeasts.
Lately, this increase has been much more associated to urinary tract
infections5,10.
The incidence of fungemia and urinary tract infections is gradually
on the rise and is an important public health problem. About 10 to 15%
of urinary tract hospital infections are due to Candida spp., and its
prevalence is still increasing2,47. Recent studies have shown that the
rate of the urinary tract infection has increased from 0.9/1000 to 2.0/
1000 patients1,3,33.
At the end of the 1980s, in the United States, 7% of the total number
of nosocomial urinary infections were caused by Candida species45.
A one-year yeast study conducted with 205 hospitalized patients,
showed that, in cases of urinary infection, 22% of the isolates belonged
to genus Candida20.
Recent studies related to urinary infections caused by Candida
spp. have focused on specific predisposing conditions, however,
particularly for children, candiduria frequency, characteristics and
implications are still unknown24. Nevertheless, candiduria can be a
precocious marker of a disseminated candidiasis, as demonstrated in a
recent study of patients in a Surgical Intensive Care Unit precociously
diagnosed with candiduria, who progressed to candidemia. Candiduria
has developed in 1.3 - 10% of the patients who previously had funguria,
and 0.4% of them evolved to death43.
Many researches showed that candiduria cases not reflect a
disseminated candidiasis but colonization or lower urinary tract
infection4,24. Often it is difficult to distinguish asymptomatic candiduria
from bladder or renal infection. Urine cultures positive for Candida
species have been noted in healthy men and women4,14.
In the present study, 100 yeast isolates obtained from children with
candiduria were identified, and their virulence factors (proteinase and
phospholipase) and killer phenotypes were investigated.
MATERIAL AND METHODS
Source of yeasts: This study involved 100 isolates of yeasts obtained
from confirmed cases of candiduria in children (zero to seven years)
hospitalized in the period from 1999 till 2004 in a Public Pediatric
Hospital in São Paulo City, SP, Brazil. This tertiary care hospital, mainly
attending a low-income population, has 90 patient beds.
Inclusion criterion: To be considered urinary yeast infection, the
yeasts have to be isolated from urine samples with counts superior to
104 UFC/mL for only one isolate and 105 UFC/mL for more than one
isolate14,21.
Yeasts identification: The yeasts were identified according to their
macroscopic, microscopic and physiological characteristics, according
to KURTZMAN & FELL23. For the identification of Trichosporon
genus, the classification recommended by GUEHO et al.15 was used.
Proteinase research: Proteinase enzyme research was carried out
according to RÜCHEL et al.37. The enzyme activity (PZ) was measured
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according to PRICE et al.35 (Pz = 1 - absence of enzyme activity =
index 1; 1.0 < Pz ≥ 0.64 - positive enzyme activity = index 2; Pz < 0.64
- strongly positive enzyme activity = index 3). C. albicans pattern
strain ICB-12A was used as a positive control.
Phospholipase analysis: Phospholipase enzyme testing was carried
out according to PRICE et al.35. C. albicans pattern strain ICB-12A
was used as a positive control.
Susceptibility to killer toxins: The Candida isolates’ susceptibility
to killer toxins was investigated by the technique described by
POLONELLI et al.36. Nine pattern strains of killer-toxin producers,
from Parma University, Italy, were used as a control.
RESULTS
The most frequent species were Candida albicans, 56.0%, followed
by C. tropicalis (20.0%), C. glabrata (11.0%), C. parapsilosis (4.0%),
C. lusitaniae, C. guilliermondii, C. krusei (2.0%) and Trichosporon
asahii (3.0%).
In regard to the production of extracellular enzymes, 84.0% of all
the isolates showed strongly positive activity for proteinase (index 3),
and 40.0% of these presented the same index for phospholipase activity.
Of the C. albicans isolates, 98.2% were proteinase producers and 17.8%
did not present phospholipase activity. All the non-albicans species
showed proteinase production. Of the 43 non-albicans isolates, 24
(55.8%) did not produce phospholipase. In regard to the three
Trichosporon asahii isolates, it was observed that only one was a
proteinase producer, while all of them did not produce phospholipase
(Table 1).
The tests for susceptibility to killer toxins resulted in eight different
biotypes. Of all 100 isolates, the most frequent biotypes were 511
(63.0%) and 888 (20.0%). The biotypes 513 and 555 were all C.
albicans, while T. asahii revealed only biotype 888 (Table 2).
DISCUSSION
The frequency of urinary tract infection caused by yeasts has
increased greatly over the last two decades due to the greater prevalence
Table 2
Sensitivity to killer toxins of 100 isolates obtained from cases of candiduria in patients hospitalized in a Public Pediatric Hospital of São Paulo, Brazil (1999-2004)
Biotypes
Species 511 513 555 587 812 887 888 111 Total
C. albicans 46 01 - 01 01 - 05 02 56
C. tropicalis 14 - 01 03 - - 02 - 20
C. glabrata 02 - - 02 - 01 06 - 11
C. parapsilosis - - - 02 - - 02 - 04
C. lusitaniae - - - - - 01 - 01 02
C. krusei - - - - - - 02 - 02
C. guilliermondii 01 - - - 01 - - - 02
T. asahii - - - - - - 03 - 03
Total 63 01 01 08 02 02 20 03 100
(63.0%) (1.0%) (1.0%) (8.0%) (2.0%) (2.0%) (20.0%) (3.0%) (100.0%)
Table 1
Proteinase and phospholipase activity presented by 100 yeast isolates obtained from cases of candiduria in children hospitalized in a Public Hospital of São Paulo,
Brazil (1999-2004)
Enzymatic Indexes
Yeast 1n (%) 2n (%) 3n (%) TOTAL
species PA PPA PA PPA PA PPA PA PPA
C. albicans (56) 1(1.8) 10(17.8) 8(14.2) 12(21.4) 47(83.9) 34(60.8) 55(98.2) 46(82.1)
C. tropicalis (20) - 12(60) 4(20) 5(25) 16(80) 3(15) 20(100) 8(40.0)
C. glabrata (11) - 6(54) - 2(18) 11(100) 3(28) 11(100) 5(45.4)
C. parapsilosis (04) - 3(75) - 1(25) 4(100) - 4(100) 1(25)
C. lusitaniae (02) - 1(50) 1(50) 1(50) 1(50) - 2(100) 1(50)
C. krusei (02) - 2(100) - - 2(100) - 2(100) -
C. guilliermondii(02) - - - 2(100) 2(100) - 2(100) 2(100)
T. asahii (03) 2(67) 3(100) - - 1(33) - 1(33) -
Total (%) (100) 3(3.7) 37(37) 13(13) 23(23) 84(84) 40(40) 97(97) 63(63) 
PA = proteolytic activity; PPA = phospholipase activity
SILVA, E.H.; RUIZ, L.S.; MATSUMOTO, F.E.; AULER, M.E.; GIUDICE, M.C.; MOREIRA, D.; SZESZS, W. & PAULA, C.R. - Candiduria in a public hospital of São Paulo (1999-2004):
characteristics of the yeast isolates. Rev. Inst. Med. trop. S. Paulo, 49(6): 349-353, 2007.
351
of prolonged hospitalization, patients with advanced age, immunocom-
promised patients; use of antibiotics; prophylaxis by antifungal agents;
use of urinary catheters; urinary tract surgical manipulation and,
especially, longer stays in intensive care units3. Catheterized patients
are at special risk, since around 26% of the urinary tract infections are
caused by fungus42.
EMORI & GAYNES9 and JARVIS17 reported that 25% of the urinary
tract infections are due to Candida genus yeasts. Candida albicans
accounts for 40 to 65% of the fungi isolated from candiduria cases31.
However, there has been an increase in the incidence of other species,
and recently it has been observed that the urinary tract is more frequently
colonized by non-albicans species than are other sites. The non-albicans
species include most notably C. glabrata, C. tropicalis, C. parapsilosis,
C. krusei, C. lusitaniae and Trichosporon spp.33.
A survey conducted from 1990 to 1991 of the aetiological agents
in urine collected in a tertiary care hospital found a 34% rise in non-
albicans species and a 11% decrease in C. albicans31. KRCMÉRY &
KOVACICOVÁ22, in a 10-year study, also verified that although C.
albicans was still the most frequently isolated species, there had been
an increase of non-albicans species from 1% in 1991 to 46.3% in 1998.
Candida albicans was identified in 61.6% of all the fungemia cases,
followed by C. parapsilosis (9.9%), C. krusei (5.8%), C. tropicalis
(4.1%) and C. glabrata (3.2%).
In the present study, C. albicans was the species most frequently
isolated, representing 56% of all the yeasts. However, other species
were isolated and the second-most frequent was C. tropicalis (20%),
followed by C. glabrata (11%). During the period from 1998 to 1999,
WEINBERGER et al.47 studied 751 patients with candiduria and found
that C. albicans was the most common species, with an incidence of
56.4%, followed by C. tropicalis (19%) and C. glabrata (15%). Other
recent studies have also observed that C. albicans is still the most
commonly isolated species, followed by C. tropicalis20,27,30. Lately,
studies have shown that C. glabrata is the second most isolated species
in candiduria cases19,40.
Significant geographic variations on the etiological pattern of
invasive Candida spp. infections have been reported in various
countries. In North America there is a predominance of C. glabrata
among non-albicans species, in South America, however, C.
parapsilosis and C. tropicalis are the predominant ones8.
These data have been confirmed by statistical studies performed
in South America that have shown the relevance of invasive infections
due to C. parapsilosis and C. tropicalis12,13,27,39. The reasons for this
inversion of the species’ distribution pattern have not yet been
completely elucidated, but may be related to the microorganisms
virulence potential and resistance to antifungals8.
For the Candida genus, one of the most studied virulence factors is
the production of extracellular enzymes, such as the secreted aspartyl
proteinase (SAPs) that hydrolyse peptide bonds, along with the
phospholipases, which hydrolyse phospholipides29.
Various studies have demonstrated that Candida albicans and other
species are proteinase and phospholipase producers, underscoring the
role that these enzymes play as virulence determinants, regardless of
the site from which they are isolated26,27,34,39. According to IBRAHIM
et al.16, Candida albicans seems to be the only Candida species which
produces phospholipase in vitro. That study also evaluated the ability
of various Candida spp. species to produce phospholipase, and found
that while 79% of the 41 C. albicans isolates produced this enzyme,
this was not the case for any of the C. tropicalis, C. glabrata or C.
parapsilosis isolates. MATSUMOTO et al.27, studying the production
of phospholipase in Candida obtained from catheter and blood, found
that while 87.5% of the C. albicans isolates produced this enzyme,
only three non-albicans isolates did. KANTARCIOGLU et al.18 verified
that while 62.1% of the non-albicans isolates showed phospholipase
activity, 93.3% of the C. albicans isolates did. RUIZ et al.39 observed
phospholipase production in 48.3% of C. albicans isolates and in 2.7%
of the non-albicans ones.
In the present study, a higher phospholipase activity was also
observed for C. albicans (82%), in comparison to non-albicans (41%)
and T. asahii (33%) isolates. This enzyme may also be used as a marker
in the diagnosis of candidiasis11.
In regard to proteinase, the enzymatic activity of C. albicans isolates
ranged from 62.5% to 100%. Experimentally, mutants deficient in terms
of proteinase production seem to be less virulent to animals than their
proteolytic relatives46.
The literature has demonstrated distinct levels of proteinase
production by different C. albicans isolates and different Candida
species. Moreover, a correlation has been demonstrated between the
level of proteinase production and virulence by species, in descending
order: C. albicans, C. tropicalis, C. parapsilosis, C. krusei, C. glabrata
and C. guilliermondii25,37,38.
SILVA et al.42 isolated C. albicans from the oral mucosa of patients
with AIDS and verified proteinase production in 100% of the isolates.
MATSUMOTO et al.27 studied 80 Candida isolates obtained from blood
and catheter and observed that 81.3% presented proteolytic activity. A
study performed by RUIZ et al.39 demonstrated a strong proteinase
activity in Candida species: 100% for C. albicans and 97.8% for non-
albicans, isolated from blood. In the present study, 98% of the C.
albicans and 100% of non-albicans species presented strong proteinase
activity.
Among the 100 isolates of the present study eight different killer
biotypes were found. The biotype most frequently encountered was
511 (63% of all the isolates), representing 82.1% of the Candida
albicans and 70.0% of the Candida tropicalis. Biotype 888, the second-
most frequent, was observed in Candida glabrata (54.5%) and Candida
parapsilosis (50.0%).
RUIZ et al.39 demonstrated six killer biotypes, while POLONELLI
et al.36, CANDIDO et al.6 and MATSUMOTO et al.27 registered,
respectively, 25, 23 and seven different biotypes. These differences
might be related to the variety of anatomical sites from which the
yeast samples were taken. Moreover, some studies have found a lower
number of killer biotypes than were encountered in these studies7,32.
The most frequent biotypes, 511 and 888, were also prevalent in
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89.6% of the Candida species isolated from the blood of hospitalized
patients25, so they are not restricted only to the urine.
According to MORACE et al.28, the use of the killer system for
differentiating isolates of pathogenic yeast species can be a useful
method for dealing with the nosocomial infections caused by these
microorganisms.
RESUMO
Candiduria em hospital público de São Paulo (1999-2004):
características das leveduras isoladas
Estudou-se 100 amostras de leveduras, isoladas de urina, provenientes
de Hospital Público Infantil de São Paulo Brasil, no período de 1999-
2004. A espécie mais freqüente foi Candida albicans, seguida de C.
tropicalis, C. glabrata e C. parapsilosis. Em relação à virulência, 97%
dos isolados apresentaram índice 3 para proteinase e, 63% índice 2 para
fosfolipase. Os biótipos “killer” mais freqüentes foram o 511 e 888.
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